Printer Friendly

Wells Fargo closed-end funds announce distributions for month.

M2 EQUITYBITES-April 29, 2019-Wells Fargo closed-end funds announce distributions for month


The Wells Fargo Income Opportunities Fund (NYSE American:EAD), the Wells Fargo Multi-Sector Income Fund (NYSE American:ERC), and the Wells Fargo Utilities and High Income Fund (NYSE American:ERH) on Saturday each declared monthly distributions.

EAD will pay a distribution of USD0.05910 per share, up from that paid earlier, ERC will pay USD0.10054 per share, up from that paid earlier and ERH will pay a distribution of USD0.07500 per share, unchanged from the earlier distribution.

With an ex-dividend date of 13 May 2019, all shareholders of record date on 14 May 2019 will be paid the distribution on 3 June 2019.

EAD is a closed-end high-yield bond fund and seeks a high level of current income and as a secondary objective, capital appreciation to the extent it is consistent with its investment objective. ERC is a closed-end income fund that also aims at a high level of current income consistent with limiting its overall exposure to domestic interest rate risk. Finally, ERH is a closed-end equity and high-yield bond fund that seeks a high level of current income and moderate capital growth with an emphasis on providing tax-advantaged dividend income.

Wells Fargo Asset Management (WFAM) is the trade name for some investment advisory/management firms owned by Wells Fargo & Compan, which include but are not limited to Wells Capital Management Incorporated and Wells Fargo Funds Management LLC. Certain products managed by WFAM entities are distributed by Wells Fargo Funds Distributor LLC (a broker-dealer and Member FINRA).

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 29, 2019
Previous Article:GSK wins US FDA priority review approval for the intravenous (IV) formulation of Benlysta in children with lupus.
Next Article:Nordic Nanovector elects Fredrik Haavind as head of Legal and Compliance.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters